spacer
home > pmps > autumn 2017 > industry insight
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Industry Insight

Many of the manufacturing processes used for the production of medicines are pretty much the same today as they were when I began my professional career over 30 years ago. This is not necessarily due to a lack of advances in manufacturing technologies that could benefit the industry. To a large extent, the inertia for adopting alternative manufacturing technologies relates to the industry fearing rejection from the regulatory authorities for introducing such changes, which is unfounded. The value of the global pharmaceutical market is estimated to be worth over $500 billion annually, therefore improvements to manufacturing efficiencies could certainly pay dividends to companies in maximising the ‘profit’ to ‘cost of goods’ ratio.

Things are changing. The regulatory organisations are encouraging pharma manufacturers to invest in and exploit advanced manufacturing technologies, and the FDA has created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing (1,2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Robert Harris, Chief Technical Officer at Juniper Pharma Services, PMPS Industry Advisor
spacer
Robert Harris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement